Dexcom's Q3 Net Income Soars 111% on Strong Revenue Growth

TL;DR

**DXCM is crushing it, with net income more than doubling – buy the dip if you get one!**

AI Summary

Dexcom Inc. reported robust financial growth for the three and nine months ended September 30, 2025. Revenue increased by 21.6% to $1,209.3 million for the three months ended September 30, 2025, up from $994.2 million in the prior year period. Net income surged by 110.8% to $283.8 million for the three-month period, compared to $134.6 million in the same period of 2024. For the nine months ended September 30, 2025, revenue grew to $3,402.4 million from $2,919.5 million, a 16.5% increase, while net income rose 34.0% to $569.0 million from $424.5 million. The company's cash and cash equivalents significantly increased to $1,835.7 million as of September 30, 2025, from $606.1 million at December 31, 2024. Total assets expanded to $7,500.0 million from $6,484.5 million over the same period. Key business changes include increased investment in research and development, which rose to $450.9 million for the nine months ended September 30, 2025, from $412.9 million in the prior year. Risks highlighted include the preliminary nature of financial information and general market uncertainties, as detailed in their Annual Report on Form 10-K.

Why It Matters

Dexcom's impressive financial performance, with over 21% revenue growth and a 111% jump in net income for the quarter, signals strong demand for its continuous glucose monitoring (CGM) systems. This growth positions Dexcom favorably against competitors like Abbott Laboratories, reinforcing its market leadership in diabetes management technology. For investors, this indicates robust operational efficiency and potential for continued shareholder value creation, especially with increased cash reserves. Employees benefit from a thriving company, while customers gain from ongoing innovation in diabetes care, driven by Dexcom's increased R&D spending. The broader market sees a healthy medical device sector, particularly in chronic disease management.

Risk Assessment

Risk Level: medium — The risk level is medium due to the cautionary note regarding forward-looking statements, indicating that actual results could differ materially from expectations. While the company shows strong financial performance with a 110.8% increase in net income for the quarter, it also highlights that information is 'of a preliminary nature and may be subject to further adjustment.' Additionally, the filing references 'risks and uncertainties identified under "Risk Factors" in our Annual Report on Form 10-K,' suggesting ongoing, albeit unquantified, operational and market risks.

Analyst Insight

Investors should consider increasing their position in Dexcom (DXCM) given the substantial revenue growth of 21.6% and net income surge of 110.8% for the quarter. The significant increase in cash and cash equivalents to $1,835.7 million provides financial flexibility for future growth initiatives and potential share buybacks, which saw $187.7 million in treasury stock purchases in the last quarter.

Financial Highlights

debt To Equity

1.75

revenue

$3,402.4M

operating Margin

17.3%

total Assets

$7,500.0M

total Debt

$2,446.8M

net Income

$569.0M

eps

$1.45

gross Margin

59.1%

cash Position

$1,835.7M

revenue Growth

+16.5%

Key Numbers

• $1,209.3M — Revenue for Q3 2025 (Increased 21.6% from $994.2 million in Q3 2024)
• $283.8M — Net income for Q3 2025 (Increased 110.8% from $134.6 million in Q3 2024)
• $3,402.4M — Revenue for nine months ended Sep 30, 2025 (Increased 16.5% from $2,919.5 million in the prior year period)
• $569.0M — Net income for nine months ended Sep 30, 2025 (Increased 34.0% from $424.5 million in the prior year period)
• $1,835.7M — Cash and cash equivalents as of Sep 30, 2025 (Increased from $606.1 million at Dec 31, 2024)
• $7,500.0M — Total assets as of Sep 30, 2025 (Increased from $6,484.5 million at Dec 31, 2024)
• $450.9M — Research and development expenses for nine months ended Sep 30, 2025 (Increased from $412.9 million in the prior year period)
• $0.70 — Diluted net income per share for Q3 2025 (Increased from $0.34 in Q3 2024)
• 390,016,272 — Common stock shares outstanding as of Oct 23, 2025 (Reflects current share count)
• $187.7M — Purchases of treasury stock for nine months ended Sep 30, 2025 (Indicates share repurchase activity)

Key Players & Entities

• DEXCOM INC (company) — registrant
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Global Select Market (market) — exchange where common stock is registered
• Abbott Laboratories (company) — competitor in CGM market
• Private Securities Litigation Reform Act of 1995 (law) — safe harbor for forward-looking statements
• Section 27A of the Securities Act of 1933 (law) — governs forward-looking statements
• Section 21E of the Securities Exchange Act of 1934 (law) — governs forward-looking statements
• Regulation FD (regulatory) — disclosure obligations

FAQ

Risk Factors

• Competition and Market Adoption [high — market]: The company faces intense competition in the diabetes management market. Failure to innovate or gain widespread adoption of its products, particularly against established players and emerging technologies, could materially impact future revenue and profitability. The market for continuous glucose monitoring (CGM) systems is dynamic and subject to rapid technological advancements.
• Regulatory Approvals and Compliance [high — regulatory]: DexCom's products are subject to stringent regulatory review and approval processes by bodies like the FDA. Delays in obtaining approvals for new products or indications, or failure to maintain compliance with evolving regulatory standards, could hinder market access and growth. The company's ability to navigate these complex regulatory landscapes is critical.
• Supply Chain and Manufacturing [medium — operational]: Disruptions in the supply chain or manufacturing processes could impact the availability of DexCom's devices. Any inability to meet demand due to production issues, raw material shortages, or quality control failures could lead to lost sales and damage customer relationships. The company relies on a complex global supply chain.
• Reimbursement and Payer Landscape [medium — financial]: The company's revenue is significantly influenced by reimbursement policies from government and private payers. Changes in coverage decisions, reimbursement rates, or the ability of patients to obtain favorable coverage for CGM devices could adversely affect sales. The ongoing evolution of healthcare economics presents a persistent risk.
• Technological Obsolescence [medium — market]: The rapid pace of technological innovation in the medical device industry poses a risk of product obsolescence. If DexCom fails to keep pace with advancements in CGM technology or alternative diabetes management solutions, its market position could be eroded. Continued investment in R&D is crucial to mitigate this risk.
• Data Security and Privacy [medium — operational]: As a connected health device company, DexCom handles sensitive patient data. Breaches in data security or privacy could lead to significant legal liabilities, regulatory penalties, and reputational damage. Robust cybersecurity measures are essential to protect user information.
• Intellectual Property Disputes [low — legal]: The company operates in an innovative field and may be subject to intellectual property disputes or litigation. Infringement claims or challenges to its patents could result in costly legal battles and potentially impact its ability to commercialize certain technologies.

Industry Context

DexCom operates in the rapidly evolving medical device sector, specifically in continuous glucose monitoring (CGM) for diabetes management. The industry is characterized by intense competition, significant R&D investment, and a strong focus on technological innovation. Key trends include the integration of CGM data with insulin delivery systems and the increasing adoption of connected health solutions.

Regulatory Implications

DexCom's business is heavily influenced by regulatory bodies like the FDA. Obtaining and maintaining approvals for its devices is critical for market access. Changes in regulatory requirements or delays in approvals can significantly impact the company's growth trajectory and product launch timelines.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-09-30: End of Third Quarter and Nine Months — Reporting period for the financial results showing significant revenue and net income growth.
• 2025-12-31: End of Fiscal Year (Prior) — Baseline for comparison of cash and cash equivalents and total assets.
• 2025-10-23: Common Stock Shares Outstanding Date — Provides an updated figure for the number of shares outstanding, relevant for EPS calculations and market capitalization.

Glossary

Condensed Consolidated Balance Sheets

A summary of a company's assets, liabilities, and equity at a specific point in time, representing the combined financial position of the parent company and its subsidiaries. (Provides a snapshot of DexCom's financial health, including its cash position, assets, and debt levels as of September 30, 2025.)

Condensed Consolidated Statements of Operations

A financial statement that reports a company's financial performance over a period of time, showing revenues, expenses, and net income. (Details DexCom's revenue growth and profitability for the three and nine months ended September 30, 2025, highlighting the significant increase in net income.)

Operating lease right-of-use assets

An asset recognized under accounting standards for leases, representing the right to use an underlying asset for the lease term. (Part of DexCom's total assets, reflecting its obligations for leased properties and equipment.)

Treasury stock

Shares of a company's own stock that it has repurchased from the open market. (Indicates DexCom's share repurchase activity, which can impact earnings per share and return capital to shareholders. The company held 20.6 million shares as treasury stock as of September 30, 2025.)

Senior convertible notes

Debt securities that can be converted into a predetermined amount of the issuer's equity. (Represents a significant portion of DexCom's long-term debt, with a current portion of $1,206.9 million and long-term portion of $1,239.9 million as of September 30, 2025.)

Accumulated other comprehensive income (loss)

A component of equity that includes unrealized gains and losses that have not yet been realized as part of net income. (Shows fluctuations in equity not directly tied to operational performance, such as foreign currency translation adjustments. It moved from a loss of ($8.0M) to a gain of $81.5M.)

Year-Over-Year Comparison

DexCom Inc. has demonstrated substantial year-over-year improvement in its financial performance. Revenue for the nine months ended September 30, 2025, increased by 16.5% to $3,402.4 million, with a more pronounced 21.6% jump in the third quarter to $1,209.3 million. Net income saw an even more dramatic rise, growing 34.0% for the nine-month period to $569.0 million and surging 110.8% in the third quarter to $283.8 million, leading to a significant increase in diluted EPS to $0.70 for Q3 2025. The company's balance sheet strengthened considerably, with cash and cash equivalents more than tripling to $1,835.7 million and total assets growing to $7,500.0 million. R&D investment also increased, reflecting a commitment to future growth.

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global

Filing Documents

• dxcm-20250930.htm (10-Q) — 1393KB
• dxcm9302025-exhibit311.htm (EX-31.1) — 10KB
• dxcm9302025-exhibit312.htm (EX-31.2) — 9KB
• dxcm9302025-exhibit321.htm (EX-32.1) — 4KB
• dxcm9302025-exhibit322.htm (EX-32.2) — 4KB
• dxcm-20250930_g1.jpg (GRAPHIC) — 108KB
• dxcm-20250930_g2.jpg (GRAPHIC) — 53KB
• dxcm-20250930_g3.jpg (GRAPHIC) — 55KB
• 0001093557-25-000280.txt ( ) — 7680KB
• dxcm-20250930.xsd (EX-101.SCH) — 40KB
• dxcm-20250930_cal.xml (EX-101.CAL) — 88KB
• dxcm-20250930_def.xml (EX-101.DEF) — 178KB
• dxcm-20250930_lab.xml (EX-101.LAB) — 556KB
• dxcm-20250930_pre.xml (EX-101.PRE) — 398KB
• dxcm-20250930_htm.xml (XML) — 1183KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION ITEM 1.

Financial Statements

Financial Statements Condensed Consolidated Balance Sheets (unaudited) as of September 30, 2025 and December 31, 2024 4 Condensed Consolidated Statements of Operations (unaudited) for the three and nine m onths ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Comprehensive Income (unaudited) for the three and nine months ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Stockholders' Equity (unaudited) for the three and nine months ended September 30, 2025 and 2024 7 Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2025 and 2024 9 Notes to Condensed Consolidated Financial Statements (unaudited) 10 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 ITEM 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 39 ITEM 4.

Controls and Procedures

Controls and Procedures 40

OTHER INFORMATION

PART II. OTHER INFORMATION ITEM 1.

Legal Proceedings

Legal Proceedings 41 ITEM 1A.

Risk Factors

Risk Factors 42 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 ITEM 3. Defaults Upon Senior Securities 44 ITEM 4. Mine Safety Disclosures 44 ITEM 5. Other Information 45 ITEM 6. Exhibits 46

Signatures

Signatures 48 2 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Except for historical financial information contained herein, the matters discussed in this Quarterly Report on Form 10-Q may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Such statements include declarations regarding our operations, financial condition and prospects, and business strategies, and are based on management's intent, beliefs, expectations, and assumptions as of the date of this report. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks, uncertainties and other factors, some of which are beyond our control. Actual results could differ materially from those indicated or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, but are not limited to: (i) that the information is of a preliminary nature and may be subject to further adjustment; (ii) those risks and uncertainties identified under "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission, or the SEC, on February 18, 2025, together with any updates identified under "Risk Factors" in our subsequently filed Quarterly Reports on Form 10-Q; and (iii) the other risks detailed from time-to-time in our other reports and registration statements filed with the SEC. Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS DexCom, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In millions, except share and par value data) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 1,835.7 $ 606.1 Short-term marketable securities 1,486.4 1,973.3 Accounts receivable, net 1,109.6 1,005.7 Inventory 604.1 542.6 Prepaid and other current assets 183.7 173.7 Total current assets 5,219.5 4,301.4 Property and equipment, net 1,471.3 1,339.9 Operating lease right-of-use assets 54.0 62.8 Goodwill 24.1 22.8 Intangibles, net 79.0 103.4 Deferred tax assets 375.6 481.2 Other assets 276.5 173.0 Total assets $ 7,500.0 $ 6,484.5 Liabilities and Stockholders' Equity Current liabilities: Accounts payable and accrued liabilities $ 1,932.4 $ 1,585.1 Accrued payroll and related expenses 170.2 112.0 Current portion of long-term senior convertible notes 1,206.9 1,204.4 Short-term operating lease liabilities 23.6 22.5 Deferred revenue 2.9 8.0 Total current liabilities 3,336.0 2,932.0 Long-term senior convertible notes 1,239.9 1,237.0 Long-term operating lease liabilities 50.6 65.0 Other long-term liabilities 147.4 147.9 Total liabilities 4,773.9 4,381.9 Commitments and contingencies (Note 5) Stockholders' equity: Preferred stock, $ 0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value, 800.0 million shares authorized; 410.6 million and 390.0 million shares issued and outstanding, respectively, at September 30, 2025; and 408.9 million and 390.7 million shares issued and outstanding, respectively, at December 31, 2024 0.4 0.4 Additional paid-in capital 2,246.5 2,093.8 Accumulated other comprehensive income (loss) 81.5 ( 8.0 ) Retained earnings 2,166.6 1,597.6 Treasury stock, at cost; 20.6 million shares at September 30, 2025 and 18.2 million shares at December 31, 2024 ( 1,768.9 ) ( 1,581.2 ) Tot